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Abstract
Background: Frail older people with multiple interacting conditions, polypharmacy, and complex care needs are particularly
exposed to health care-related adverse events. Among these, anticoagulant-related thromboembolic and hemorrhagic events are
particularly frequent and serious in older inpatients. The growing use of anticoagulants in this population and their substantial
risk of toxicity and inefficacy have therefore become an important patient safety and public health concern worldwide.
Anticoagulant-related adverse events and the quality of anticoagulation management should thus be routinely assessed to improve
patient safety in vulnerable older inpatients.
Objective: This project aims to develop and validate a set of outcome and process indicators based on linked administrative
health data (ie, insurance claims data linked to hospital discharge data) assessing older inpatient safety related to anticoagulation
in both Switzerland and France, and enabling comparisons across time and among hospitals, health territories, and countries.
Geriatric patient safety indicators (GPSIs) will assess anticoagulant-related adverse events. Geriatric quality indicators (GQIs)
will evaluate the management of anticoagulants for the prevention and treatment of arterial or venous thromboembolism in older
inpatients.
Methods: GPSIs will measure cumulative incidences of thromboembolic and bleeding adverse events based on hospital discharge
data linked to insurance claims data. Using linked administrative health data will improve GPSI risk adjustment on patients’
conditions that are present at admission and will capture in-hospital and postdischarge adverse events. GQIs will estimate the
proportion of index hospital stays resulting in recommended anticoagulation at discharge and up to various time frames based on
the same electronic health data. The GPSI and GQI development and validation process will comprise 6 stages: (1) selection and
specification of candidate indicators, (2) definition of administrative data-based algorithms, (3) empirical measurement of indicators
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using linked administrative health data, (4) validation of indicators, (5) analyses of geographic and temporal variations for reliable
and valid indicators, and (6) data visualization.
Results: Study populations will consist of 166,670 Swiss and 5,902,037 French residents aged 65 years and older admitted to
an acute care hospital at least once during the 2012-2014 period and insured for at least 1 year before admission and 1 year after
discharge. We will extract Swiss data from the Helsana Group data warehouse and French data from the national health insurance
information system (SNIIR-AM). The study has been approved by Swiss and French ethics committees and regulatory organizations
for data protection.
Conclusions: Validated GPSIs and GQIs should help support and drive quality and safety improvement in older inpatients,
inform health care stakeholders, and enable international comparisons. We discuss several limitations relating to the
representativeness of study populations, accuracy of administrative health data, methods used for GPSI criterion validity assessment,
and potential confounding bias in comparisons based on GQIs, and we address these limitations to strengthen study feasibility
and validity.
(JMIR Res Protoc 2017;6(5):e82)   doi:10.2196/resprot.7562
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Introduction
Background
People aged 65 years and over are the most frequent users of
acute care hospitals in Europe, and aging trends among hospital
inpatients are expected to increase dramatically in the next
decades [1,2]. However, acute care hospitals often deliver
substandard care to older people with complex care needs [3].
Moreover, frailty, chronic multimorbidity, disability,
polypharmacy, and the resulting clinical and organizational
complexity of care [4] expose older inpatients to an increased
risk of hospital care-related adverse events [5-7]. A literature
review not only confirmed the high incidence of adverse events
among older inpatients, accounting for 5% to 60% of admissions
in acute care hospitals, but also highlighted the strong
association between adverse events and hospital care quality,
with more than 50% of these events being deemed preventable
[7]. These adverse events have important consequences for older
patients, as they accelerate the aging process and lead to loss
of autonomy, frequent and longer hospitalization,
institutionalization, and finally death [4,6,7]. Adverse events
also worsen patients’ experience with hospital care and affect
their quality of life [4,8]. Finally, they weigh on health services
utilization and costs [4,6].
Like most countries, Switzerland and France have initiated
systemic reforms to move toward a more sustainable health care
system and meet the challenges of aging and chronic
multimorbidity [9]. Both governments give priority to health
care quality improvement in older patients and foster the
provision of better data to inform health policy, promote
transparency, and improve health care efficiency [10-15].
Indeed, quality and safety indicators targeting older inpatients
are essential to support and drive quality improvement, as well
as inform health care stakeholders. These indicators are also of
great interest to compare the performance of various health
systems [16]. Some commonly used indicators based on large
administrative health databases (eg, hospital discharge and
insurance claims databases) could help assess and compare
patient safety and health care quality across hospitals and health
territories in both countries. They could also enable comparisons
of Swiss and French health systems’ performance in providing
high-quality, safe care to vulnerable older inpatients [12,15],
which are a source of “cross-country learning” and improvement
[17,18]. For example, the Patient Safety Indicators (PSIs) [19],
which have been developed by the US Agency for Healthcare
Research and Quality (AHRQ) [19] and adopted internationally
[20,21], could screen acute hospital discharge data for potentially
avoidable adverse events occurring during hospitalization.
Similarly, PSIs adapted to linked administrative health data (ie,
hospital discharge data linked to insurance claims data) could
be of use to monitor in-hospital and postdischarge adverse
events, as the latter may reflect delayed and poor quality of
hospital care or premature discharge from hospital [22]. Finally,
some of the Assessing Care of Vulnerable Elders-3 (ACOVE-3)
quality indicators could evaluate health care processes and
medication management in older inpatients based on
administrative data [3,23].
Among adverse events affecting older inpatients,
anticoagulant-related thromboembolic and hemorrhagic adverse
events are especially frequent and serious; in fact, age is one of
the strongest predictors of venous or arterial thromboembolism
and bleeding during anticoagulation [24-26]. Furthermore,
thromboprophylaxis is frequently suboptimal in older inpatients
despite the availability of professional guidelines [27]; many
studies have indeed reported recurrent prescriptions of
supratherapeutic doses of anticoagulants, as well as frequent
underuse and rare risk-benefit assessment of anticoagulation in
this population [26-30]. Finally, the growing use of
anticoagulants, especially of direct oral anticoagulants, in the
geriatric inpatient population and their substantial risk of toxicity
and inefficacy have become an important patient safety and
public health concern worldwide [25,31]. Anticoagulant-related
adverse events and the quality of anticoagulation management
should therefore be routinely assessed in older inpatients
receiving anticoagulants for the prevention and treatment of
arterial or venous thromboembolism.
JMIR Res Protoc 2017 | vol. 6 | iss. 5 | e82 | p.2http://www.researchprotocols.org/2017/5/e82/
(page number not for citation purposes)
Le Pogam et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
Two PSIs can be used to monitor potentially avoidable
perioperative thromboembolic or bleeding events in older Swiss
and French inpatients: PSI-12, Perioperative Pulmonary
Embolism or Deep Vein Thrombosis Rate, and PSI-09,
Perioperative Hemorrhage or Hematoma Rate [19,20,32-34].
Indeed, although both indicators target adult inpatients, most
corresponding adverse events affect inpatients aged 65 years
and over [20]. Moreover, PSI-12 has been adapted to coding
systems of various countries, including Switzerland and France
[21,35]. Lastly, both algorithms have been extended to capture
both in-hospital and postdischarge adverse events based on
hospital discharge data linked to outpatient claims data [22].
Besides these perioperative PSIs, others should be developed
to monitor adverse events related to venous thromboembolism
curative treatments and thromboprophylaxis in at-risk medical
conditions such as severe acute infection or atrial fibrillation.
Case-mix adjustment of PSIs should also be considered to
account for differences in older inpatients’ clinical risks or
disease severity at admission [4] and enable comparisons across
hospitals or geographic areas [36,37]. In particular, PSIs should
be adjusted for older inpatients’ risk factors for both hospital
care-related adverse events (eg, frailty, chronic multimorbidity,
disability, or polypharmacy) and thromboembolic or
hemorrhagic adverse events (eg, age ≥75 years, renal or liver
failure, inherited or acquired disorders of hemostasis,
malignancy). Thus, besides the Charlson comorbidity index
[38] and the updated chronic disease score [39], which have
already been adapted to Swiss and French administrative health
data, other comorbidity indexes [40], proxy measures of frailty
and disability [41,42], and individual risk scores of
thromboembolism or hemorrhage [43,44] should also be
developed or adapted [45].
Regarding process quality metrics, three ACOVE-3 indicators
may be used to evaluate warfarin prescription and surveillance
in older patients with heart failure or atrial fibrillation [23].
Additional indicators should be developed to assess the
management of other anticoagulants, including direct oral
anticoagulants.
Objectives
This research project aims to develop and validate a set of
outcome and process indicators based on linked administrative
health data (ie, insurance claims data linked to hospital discharge
data) assessing older inpatient safety related to anticoagulation
in both Switzerland and France, and enabling comparisons
across time and among hospitals, health territories, and
countries.
The project will thus comprise complementary steps aiming to
(1) develop and validate a set of geriatric patient safety
indicators (GPSIs) assessing in-hospital and postdischarge
anticoagulant-related adverse events in older inpatients; (2)
adapt the PSI-09 and PSI-12 to Swiss and French linked data;
(3) develop a set of geriatric quality indicators (GQIs) assessing
the management of anticoagulants for the prevention and
treatment of arterial or venous thromboembolism based on Swiss
and French data; (4) develop or adapt chronic multimorbidity
indexes, proxy measures of frailty and disability, and
thromboembolic and bleeding risk scores based on Swiss and
French data to adjust GPSIs on case mix; and (5) compare
anticoagulation safety within and between Switzerland and
France.
Methods
Development and Validation Process
We will develop and validate GPSIs according to the
methodology used by the AHRQ [46-48], which comprises 6
standardized sequential stages (Figure 1).
Selection and Specification of Candidate GPSIs
We will use a modified Delphi method [49] combining evidence
from a systematic literature review with the collective judgment
of clinical experts (clinical panel) to select candidate indicators
and define their specifications (numerator, denominator,
risk-adjustment factors, and measurement time frame for
postdischarge adverse events). These candidate GPSIs will
measure the cumulative incidences of thromboembolic and
hemorrhagic adverse events for selected surgical procedures or
medical conditions (Textbox 1).
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Figure 1. Summary of the geriatric patient safety indicator (GPSI) development and validation process. GQI: geriatric quality indicator; NPV: negative
predictive value; PPV: positive predictive value; Se: sensitivity; Sp: specificity.
Textbox 1. Candidate geriatric patient safety indicators (GPSIs) and geriatric quality indicators (GQIs) assessing older inpatient safety regarding
anticoagulation.
GPSIs
Cumulative incidence of in-hospital and postdischarge anticoagulant-related adverse events:
1. Venous thromboembolism or hemorrhagic events in surgical patients
• High-risk surgery (eg, total hip or knee arthroplasty)
• Moderate-risk surgery (eg, abdominal and pelvic surgery)
• Low-risk endoscopic surgery or diagnostic procedures (eg, colonoscopy)
2. Venous thromboembolism or hemorrhagic events in medical patients
• Acute medical conditions (eg, severe acute infection, acute heart failure, nonsurgical trauma)
• Chronic conditions (eg, cancer, chronic inflammatory diseases)
3. Strokes and other systemic arterial embolisms or hemorrhagic events in patients with atrial fibrillation
4. Recurrent venous thromboembolism or hemorrhagic events in patients with venous thromboembolism
5. Adapted Patient Safety Indicator (PSI) -12 (perioperative thromboembolism)
6. Adapted PSI-09 (perioperative hemorrhagic event)
GQIs
For each GPSI, 2 GQIs assessing the management of anticoagulant treatments:
1. Proportion of index hospital stays resulting in the recommended anticoagulation (drug, dose, frequency, duration) at and after discharge
2. Median duration of anticoagulant treatment after discharge for index hospital stays
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Definition of Administrative Data-Based Algorithms
GPSI algorithms will be determined by Swiss and French
administrative health data experts (coding panel) during a
face-to-face meeting. The coding panel will first determine the
feasibility of measuring candidate indicators and risk-adjustment
factors using administrative health data, and, second, select the
diagnosis, procedure, and drug codes to be included in and
excluded from their calculation.
Empirical Measurement
We will empirically measure crude and risk-adjusted GPSIs
retained at the end of the second stage at the hospital, territorial,
and national levels for the years 2012 to 2014 using Swiss and
French data. We will conduct sensitivity analyses to assess the
impact of different definitions and selected codes on the
robustness of empirical results. This stage will also aim to
explore the consistency of the empirical results with the
literature, highlight variations in indicators across hospitals or
health territories, and examine potential bias related to
insufficient adjustment on patient case mix or variation in coding
practices. We will exclude GPSIs not performing well from the
validation stage.
Validation of GPSIs
We will test the reliability and validity of retained GPSIs using
a comprehensive validation framework. (1) Face and content
validity assessment: the apparent and content relevance of GPSIs
will be discussed by the clinical and coding panels. (2) Criterion
validity assessment: we will assess the algorithm accuracy of
each retained GPSI by measuring its performance in identifying
the corresponding adverse event compared with a reference
standard (medical record screening). GPSIs with low sensitivity
(<75%) or low positive predictive value (PPV) (<75%) will be
excluded from the candidate list [50]. We will similarly assess
the accuracy of the algorithm developed for each case-mix factor
based on coded administrative health data. (3) Construct validity
assessment: we will verify statistical associations among
unadjusted GPSIs, between unadjusted GPSIs and related
process indicators, and between unadjusted GPSIs and other
unadjusted outcome indicators assessing the same care processes
(eg, mortality rates, length of stay, and potentially avoidable
readmissions rates). GPSIs with nonsignificant or inconsistent
correlations will be excluded from further development and
validation processes. (4) Predictive validity assessment: finally,
for each remaining GPSI, we will assess the statistical
performance of its risk-adjustment model in accounting for
actual differences in case mix, and therefore in predicting the
related outcome, by measures of its calibration and
discriminatory power.
Analyses of GPSI Geographic and Temporal Variations
(1) We will analyze geographic variations at the hospital and
territorial levels using funnel plots to identify outliers. Statistical
modeling will identify potential causes of systematic variations
related to the health system or the quality of care. (2) We will
study temporal variations in monthly or quarterly measures of
GPSIs for the period 2012-2014 at the national and territorial
levels using statistical models to identify potential trends and
explanatory factors. We will also study temporal variations at
the hospital level, hospital legal status level (ie, public, private
not-for-profit, and private for-profit), and hospital volume level
(ie, tertiles or quintiles of annual index hospital stays eligible
for GPSI denominator) using control charts to identify special
causes of variation related to the quality of the health care
processes.
Data Visualization
For both Switzerland and France, we will construct comparative
graphic displays of the anonymized results for scientific, public,
or institutional reporting. They will comprise (1) a Swiss and
French atlas documenting territorial variations in risk-adjusted
GPSIs; (2) funnel plots reflecting between-hospital and
between-hospital category variations in risk-adjusted GPSIs;
(3) individual control charts of risk-adjusted GPSIs displaying
temporal variations for each hospital, hospital category, and
territory; and (4) national, territorial, and individual temporal
trends in GPSIs over the period 2012-2014.
Regarding GQIs, the clinical panel will select candidate
indicators among those suggested in Textbox 1. We will then
apply a similar development and validation process, except for
criterion and predictive validity assessment. Indeed, as
anticoagulant treatments (drug, dose, frequency, and duration)
coded in insurance claims data reflect quite precisely the ones
that were prescribed and reimbursed, GQI algorithms should
be accurate for assessing the management of anticoagulants at,
and after, discharge. In addition, we will not be able to access
outpatient medical records, which would constitute the suitable
reference standard for testing the accuracy of GQIs. We will
not assess the predictive validity of GQIs because process
indicators do not require case-mix adjustment when comparing
hospitals or health territories. Indeed, the quality of hospital
care processes does not usually depend on inpatient case mix
[37,51].
GPSI and GQI Development
Study Design
To develop GPSIs or GQIs, we will conduct multicenter
retrospective observational cohort studies based on insurance
claims data individually linked to hospital discharge data.
Population Setting
In Switzerland, the study population will consist of all residents
aged 65 years and over admitted to a Swiss acute care hospital
at least once between 2012 and 2014 (ie, the inclusion period)
and insured under the compulsory basic health insurance scheme
by Helsana Group for at least 1 year before admission and 1
year after discharge. Helsana is one of the 3 biggest insurance
groups in Switzerland, covering approximately one-fifth of the
Swiss population aged 65 years and over [52].
Inclusion criteria for the French study population will be similar
except that they will target older residents admitted to a French
acute care hospital and insured under the general scheme by the
National Health Insurance Fund for Salaried Workers (Caisse
Nationale d’Assurance Maladie des Travailleurs Salariés
[CNAMTS]). This scheme covers approximately 69% of the
French population aged 65 years and over (2014 data provided
by CNAMTS).
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We will exclude from both study populations patients for whom
(1) 2012-2014 administrative health data were incomplete, (2)
individual data linking was not possible, and (3) hospital length
of stay was less than 2 days.
Candidate GPSIs and GQIs
AHRQ PSIs are measures based on administrative health data
that “screen for adverse events that patients experience as a
result of exposure to the healthcare system, and that are likely
amenable to prevention by changes at the system or provider
level” [19]. Likewise, candidate GPSIs will screen Swiss and
French linked administrative data for thromboembolic or
hemorrhagic adverse events that resulted from exposure to
medical or surgical conditions requiring anticoagulant
treatments, and occurred during hospital stay or after discharge
(Textbox 1). Hospital-level GPSIs will measure, for each acute
care hospital, the cumulative incidences of in-hospital and
postdischarge anticoagulant-related adverse events and be
defined with a denominator (ie, index stays in a given hospital
within a 1-year period) and a numerator (ie, denominator stays
resulting in the adverse event of interest during hospitalization
and up to 30 days, 60 days, 90 days, 6 months, and 1 year after
discharge). For example, the denominator of the GPSI that will
measure the 2012 cumulative incidence of in-hospital and 30-day
postdischarge hemorrhagic events for older patients receiving
venous thromboprophylaxis after elective total hip arthroplasty
will include any 2012 hospital stay for elective total hip
arthroplasty, excluding 1-day surgery, of patients aged 65 years
and over. Indeed, older patients undergoing elective total hip
arthroplasty are supposed to receive the appropriate venous
thromboprophylaxis, as they are considered to be at high risk
of thromboembolic and hemorrhagic events [53]. The numerator
will comprise any hemorrhage [54] occurring during index
hospital stays and up to 30 days after the patients’ discharge
dates. The hospital that performed the total hip arthroplasty
procedure will be held accountable for the index stay and
hemorrhage. We will identify index stays and hemorrhages
using hospital discharge data and linked administrative health
data, respectively.
For each GPSI, 2 GQIs will measure for each hospital (1) the
proportion of index hospital stays resulting in the recommended
anticoagulation (drug, dose, frequency, and duration) at
discharge, and up to 30 days, 60 days, 90 days, 6 months, and
1 year after discharge; and (2) the median duration of
recommended anticoagulant treatment after discharge for index
hospital stays. For example, the GPSI described above will be
completed by the following GQIs: (1) the proportion of 2012
hospital stays for elective total hip arthroplasty in patients aged
65 years and over resulting in the recommended anticoagulation
(drug, dose, frequency, and duration) at and up to 30 days after
discharge; and (2) the median duration of recommended
anticoagulant treatment after discharge for these index stays.
We will extract information on anticoagulant treatments after
hospital discharge from insurance claims data.
Administrative Health Data Scope and Time Frame
We will extract Swiss administrative health data from the
Helsana Group data warehouse and will include 2010-2015
insurance claims data individually linked to 2012-2015 acute
care hospital discharge data and individual measures of
dependency for nursing home residents. Since data collection
of inpatient diagnosis and procedure codes and dependency
measures started in 2012, only insurance claims data will be
available for the period 2010-2012.
We will extract French data from the national health insurance
information system (Système National d’Information
Inter-Régimes de l’Assurance Maladie [SNIIR-AM]) hosted by
CNAMTS [55]. Since 2007, SNIIR-AM has included
individually linked data from various administrative databases
for the entire French population: all hospital discharge data (ie,
discharge data from acute, postacute, rehabilitation, psychiatric,
and long-term care hospitals and from hospital-at-home
facilities); insurance claims data; data on nursing homes
residents; and data on health professionals’ characteristics. We
will include only those patients insured under the general
scheme, as vital status and death date are exhaustive only for
these patients.
Multimedia Appendix 1 comprehensively describes Swiss and
French data, including linkage methods and success rates.
In both countries, we will identify index hospital stays and
in-hospital adverse events from 2012-2014 hospital data and
adverse events up to 1 year after discharge from 2012-2015
linked hospital and insurance data (Textbox 2). Similarly, we
will test anticoagulation management up to 1 year after discharge
over the period 2012-2015 using linked data (Textbox 2). GPSI
risk-adjustment factors will be estimated using data from
2010-2014 to account for patient conditions up to 2 years before
their admission. Since hospital discharge data will not be
available for the period 2010-2012 in Switzerland, we will derive
risk-adjustment factors from insurance claims data only
(Textbox 2).
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Textbox 2. Geriatric patient safety indicator (GPSI) and geriatric quality indicator (GQI) measurement time frames.
GPSIs
Inclusion period for index hospital stay (denominator)
• Discharge date between January 1, 2012 and December 31, 2014
Follow-up period for adverse event screening (numerator)
• From admission date of index hospital stay up to 1 year after discharge date of index hospital stay
Inclusion period for case-mix factors present at admission (risk adjusters)
• Up to 2 years before admission date of index hospital stay
GQIs
1. Proportion of index hospital stays resulting in the recommended anticoagulation at and after discharge
Inclusion period for index hospital stay (denominator)
• Discharge date between January 1, 2012 and December 31, 2014
Follow-up period for prescription of anticoagulant treatment (numerator)
• Up to 1 year after discharge date of index hospital stay
2. Median duration of anticoagulant treatment after discharge for index hospital stays
Follow-up period for prescription of anticoagulant treatment
• Up to 1 year after discharge date of index hospital stay
GPSI Criterion Validity Assessment
Study Designs
The study design considered to assess the criterion validity of
each GPSI will be a multicenter cross-sectional study with a
test-based enrollment approach [56].
Population Settings
For each GPSI, the study population will comprise all older
insured patients who were admitted to an acute care hospital
between 2013 and 2014 and were at risk for the related adverse
event (GPSI denominator population). Whereas any acute care
hospital may be included in the Swiss validation study, the
French study will target acute care hospitals located in the
Burgundy-Franche-Comté region, which hosts Dijon University
Hospital (ie, the French collaborative research center). Indeed,
as these studies are time and resource consuming, it is necessary
to balance representativeness against efficiency. For both
countries, exclusion criteria will include an insufficient number
of at-risk admissions over the 2 years 2013 and 2014 (≤50 stays)
and a hospital’s refusal to participate.
Data Source and Criterion Validity Metrics
We will assess GPSI accuracy by measuring the performance
of the algorithm in identifying corresponding adverse events
based on administrative health data compared with a reference
standard (medical record screening). We will identify GPSI+
(ie, complicated) and GPSI– (ie, uncomplicated) hospital stays
from administrative data based on the algorithm. Then, we will
randomly select a sample of these GPSI+ and GPSI– stays and
verify whether an adverse event is recorded in the corresponding
medical record. GPSI criterion validity will then be assessed
based on the sensitivity, specificity, PPV, and negative
predictive value of the algorithm.
Planned Statistical Analyses and Sample Size
Calculation
Statistical analyses will be performed using Stata/MP software
version 14 for Windows (StataCorp LLC) or SAS/STAT
software, version 9.4 of the SAS system for Windows (SAS
Institute Inc).
Indicator Calculation and Case-Mix Adjustment
GPSIs will provide yearly (2012-2014) observed cumulative
incidences of thromboembolic and bleeding adverse events in
selected surgical procedures or medical conditions (Textbox 1)
for each hospital, hospital legal status, hospital volume category,
health territory (ie, Swiss cantons and French departments), and
country. We will calculate these incidences as the proportion
of at-risk hospital stays resulting in in-hospital or postdischarge
adverse events over a year. To allow comparisons across
hospitals and health territories, we will adjust GPSIs on patient
case mix (eg, age, sex, multimorbidity, frailty, disability,
polypharmacy, point of origin for admission, admission mode,
thromboembolic or hemorrhagic individual score, and local
health care capacity) using multilevel logistic regression
modeling accounting for the hierarchical structure of the data.
Every GPSI risk-adjustment model will undergo a 3-fold
cross-validation, in which we will use a random sample
comprising one-third of the whole data to develop the empirical
model (development dataset), another one-third to estimate the
parameters (estimation dataset), and the remaining one-third to
test the predictive validity of the model (validation dataset) [57].
The predictive validity of the model will be assessed by
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measures of its calibration (Hosmer-Lemeshow goodness-of-fit
test) and discriminatory power (C statistic) [58]. We will provide
expected cumulative incidences with their 95% confidence
intervals.
We will calculate GQIs as (1) the proportion of at-risk hospital
stays resulting in the recommended anticoagulation (drug, dose,
frequency, and duration) at discharge and up to 30 days, 60
days, 90 days, 6 months, and 1 year after discharge; and (2) the
median duration of recommended anticoagulant treatment after
discharge for index hospital stays. Anticoagulation management
for selected at-risk conditions (Textbox 1) will be assessed at
the hospital, hospital legal status, hospital volume category,
territorial, and national levels and for each year of the inclusion
period. Process indicators will not be risk adjusted.
Case-Mix Factor Calculation
Case-mix factors usually considered for PSI risk adjustment
include age, sex, past medical history, point of origin for
admission, admission mode, and comorbidity present at
admission [19,36]. We will also consider other important
predictors of adverse health outcomes, including
thromboembolic or hemorrhagic events, in older inpatients. To
this end, multimorbidity, polypharmacy, frailty, and disability
indexes based on Swiss and French administrative health data
will be purposely developed or adapted from already validated
ones [38-40,59-62]. Although these conditions are considered
as separate clinical entities and independently associated with
poor outcomes, they overlap significantly and are causally
interrelated [4,41,61,63]. Consequently, risk-adjustment models
will also account for possible interactions or associations
between these various case-mix variables. We will also consider
a single proxy measure of older inpatient complexity—similar
to the Charlson and Elixhauser indexes—that could encompass
all these conditions. GPSIs will also be adjusted on individual
thromboembolic or bleeding risk scores, including venous
thromboembolism risk scores for surgical patients (Caprini and
Rogers scores) [44], ischemic stroke risk scores for patients
with atrial fibrillation (CHA2 DS2-VASc or ATRIA score) [43],
and a major bleeding risk score for patients on anticoagulation
(HAS-BLED) [43]. CHA2 DS2-VASc and HAS-BLED have
already been estimated based on French data [45] and will be
adapted to Swiss data. We will develop the remaining scores in
both countries.
Studies of GPSI and GQI Geographic and Temporal
Variations
We will study variations across hospitals, hospital legal status,
hospital volume categories, and health territories using (1) funnel
plots to identify potential outliers [64-66]; (2) hierarchical
logistic regression models to identify potential causes of
systemic variations related to the health system (eg, health care
supply, including specialized geriatric units or professionals in
hospitals; availability of integrated care organizations; health
policy strategy supporting patient safety) or to the quality of
care (eg, availability of professional guidelines, adherence to
treatment and surveillance standards regarding anticoagulation);
and (3) propensity score-based risk-adjustment models to
estimate the performance of the different hospitals assessed by
validated GPSIs or GQIs [67].
We will study monthly or quarterly variations in GPSIs and
GQIs over the inclusion period at the national and territorial
levels using multilevel logistic regression modeling for repeated
measures to identify potential trends and explanatory factors
(eg, changes in anticoagulation guidelines, coding rules, or
classifications, Diagnosis-Related Group (DRG) system, or drug
and procedure reimbursement limits). We will also assess
temporal variations at the hospital, hospital legal status, and
hospital volume levels using control charts, including p-charts
and cumulative sum charts [68-71], to identify special causes
of variation related to the quality of health care processes.
Comparisons of Anticoagulant-Related Safety Between
Switzerland and France
We will compare GPSIs measured at the national level between
Switzerland and France using direct age and sex standardization,
as recommended by the Organisation for Economic Co-operation
and Development [16]. Indeed, age and sex standardization
enable accounting for between-country differences in population
structures, including general and inpatient populations, and
practices regarding older inpatients’ hospitalization in acute
care [21]. For each GPSI, aggregated nationwide counts of index
hospital stays stratified by age and sex will define the internal
reference population. We will then calculate a comparative
morbidity figure (ie, the ratio of directly age- and
sex-standardized adverse event rates in Switzerland and France)
along with its 95% confidence interval. Moreover, to account
for differences in coding systems, we plan to adjust national
measures of GPSIs on the mean number of secondary diagnoses
among denominator cases [21].
Results
Administrative Health Data and Study Populations
After accounting for inclusion and exclusion criteria, we will
include 166,670 Swiss and 5,902,037 French residents aged 65
years and over in our study. Multimedia Appendix 1
comprehensively describes Swiss and French data available for
our study, along with data linkage methods and success rates.
Sample Size Calculation for GPSI Criterion Validity
Assessment
For sample size calculation, we used a test result-based sampling
method [72] to minimize the number of medical records to be
abstracted. We estimated optimal sample sizes, as well as
sampling fractions of GPSI+ and GPSI– medical records to be
abstracted, for prevalence (ie, proportion of medical records in
which at least 1 adverse event was recorded) ranging from 0.4%
to 5%, a desired algorithm sensitivity of 75%, a 20% width for
sensitivity 95% confidence interval, and unknown numbers of
at-risk stays (ie, unknown GPSI denominators). We extracted
prevalence values and PPVs from the literature
[16,24,32-34,44,50,73-75] and calculated sample size using
Stata/IC software version 13 (see Multimedia Appendix 2).
Thus, assuming a prevalence of 2%, an optimal sample of 3164
medical records should be randomly selected from participating
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hospitals and abstracted: 126 GPSI+ and 3038 GPSI– medical
records. These results are consistent with the literature [73].
Ethical and Regulatory Aspects
The research project was approved by the Cantonal Ethics
Commission of Vaud (Switzerland) in August 2016 (Decision
CER-VD 2016-00508) and by the French data protection
authority (Commission National de l’Informatique et des
Libertés) in March 2016 (Decision DE-2016-036).
Timetable of the Project
All administrative health data are now available to the Swiss
and French research teams. The research project will run until
the end of 2018.
Discussion
Main Strengths of the Study
First, to our knowledge, this is the first study aiming at
developing and validating a set of geriatric quality and safety
indicators based on linked administrative health data, both in
Switzerland and in France. Assessing the quality and safety of
anticoagulation in older inpatients based on such data is also
innovative. Indeed, in addition to using extended PSI-09 and
PSI-12, which capture perioperative adverse events up to 30
days after discharge [22], we will develop and validate a set of
GPSIs assessing thromboembolic or bleeding adverse events
for various surgical procedures or medical conditions requiring
curative or prophylactic anticoagulation. Similarly, our set of
validated GQIs will complement the ACOVE-3 quality
indicators based on administrative health data assessing warfarin
prescription and surveillance in older patients with heart failure
or atrial fibrillation [23]. In particular, they should provide useful
information on direct oral anticoagulant management.
Second, validated GPSIs will account for an older inpatient case
mix, which is crucial when comparing hospitals or health
territories. Specific indexes based on Swiss and French
administrative health data, including multimorbidity,
polypharmacy, frailty, and disability indexes, will thus be
purposefully developed or adapted from existing ones to target
older inpatients’ conditions at admission [38-40,59-62]. These
important predictors of adverse health outcomes (ie, mortality,
morbidity, dependency, and institutionalization), health-related
quality of life, and resource use [38,40,59] may be used not
only as risk-adjustment factors for other health care quality and
safety indicators, but also as screening tools for older patients’
vulnerability in various health care settings. Indeed, many
countries, including France, try to implement frailty or
vulnerability screening and management programs (eg, the
French initiative “parcours de santé pour les personnes âgées
en risque de perte d’autonomie” [PAERPA]) to avoid
institutionalization and hospitalization, improve older citizens’
quality of life, and reduce health care costs [76,77]. Finally,
assessing patient complexity and vulnerability, both at the
individual and population levels, may contribute to better
planning of appropriate health and social care services [76,77].
Developing or adapting individual thromboembolic or bleeding
risk scores based on administrative health data is the third major
strength of our study. These scores will be included in GPSI
risk-adjustment models and may also contribute to assessing
the quality of anticoagulant management by comparing patients’
risks with the treatment they actually received. Indeed, decisions
regarding anticoagulant treatments (ie, type, dose, frequency,
and duration) and surveillance should be consistent with
risk-benefit assessment, especially in the older inpatient
population, which is highly exposed to anticoagulant-related
thromboembolic or bleeding complications. Furthermore,
complementing individual scores with patient outcomes (ie,
GPSIs) and data on anticoagulant management (ie, GQIs) should
enrich information on effectiveness and safety of anticoagulants
in “real life,” in particular direct oral anticoagulants, and
eventually help improve professional guidelines [25,26,30,31].
Fourth, our project will enable comparisons of GPSIs and GQIs
between Switzerland and France, which is a source of
cross-country learning and performance improvement [17,18].
Indeed, despite having different organization, governance, and
financing, and serving different populations, Swiss and French
health systems “have similar goals and face similar challenges,
such as demographic change, limited resources and rising costs”
[17,18]. Between-country comparisons should thus help study
differences in (1) linked administrative health data features,
quality, regulation, and coding rules; (2) older inpatients’ and
health care providers’ characteristics; (3) quality standards on
and safety of anticoagulant management in older inpatients; and
(4) health care policy and reforms toward transparency,
accountability, and high-quality safe care to vulnerable older
inpatients [12,15].
Study Limitations
Our study has several limitations that should be considered
when interpreting the results. First, our study populations may
not be representative of all Swiss and French older inpatients.
Indeed, Swiss data cover approximately 18% of the Swiss
population aged 65 years and over [52], and policy holders
residing in German-speaking cantons are overrepresented
compared with others. French data include a very large
population of nearly 6 million persons, namely 69% of the
French insured aged 65 years and over. However, only salaried
or retired employees are represented, while other professional
subgroups and enrollees in 1 of the 16 specific insurance
schemes (eg, soldiers, miners, ministers of religion, and
employees of the French National Railway Company) are
excluded from the study population [55]. As insured or cultural
groups may differ in their risk factors, compliance with
anticoagulant treatments, access to and utilization of health
services, and geographic distribution (eg, employees may be
underrepresented in rural areas), the internal and external validity
of our study might be affected by selection bias [78]. Albeit
figuring that this bias should not significantly affect our
indicators, we will thus generalize our findings to the study
populations and gather information on older inpatients excluded
from our study. In particular, we will make a request to
CNAMTS to access their data on French residents enrolled in
other schemes than the general one. French data will thus cover
the entire population.
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Second, insurance claims data may also be incomplete or
“selected.” For example, they will not include coded diagnoses
on adverse events occurring in outpatient settings and will not
provide information on patients’ adherence to treatment and
surveillance. However, we expect to capture almost all
postdischarge adverse events by screening readmissions,
prescriptions or modifications of anticoagulant or
antihemorrhagic treatments, outpatient procedures (eg, lower
limb venous ultrasonography), and laboratory tests (eg,
hemoglobin and international normalized ratio tests). Moreover,
we believe that the quality of anticoagulant management is
accurately assessed using large administrative databases linked
over time. Swiss insurance claims may also be missing
differentially according to health insurance deductibles (ie, SwF
300 to 2500 per year) [78-80]. Indeed, policyholders with the
highest deductibles tend not to claim reimbursement of medical
expenses when their annual amount does not reach the
deductible, which leads to missing claims. However, this
potential selection bias should not be significant, since health
insurers estimate that only 2% to 3% of all invoices are not sent
for reimbursement [52]. Finally, French data from SNIIR-AM
may also lack some information regarding fully reimbursed
long-term conditions. Indeed, long-term conditions are often
underreported in patients fully covered for several long-term
conditions or benefiting from a complementary insurance, or
in nursing home residents [81]. We will overcome this limitation
by deducing missing long-term conditions from medications
coded in insurance claims or from diagnoses coded in hospital
discharge records.
Third, hospital discharge data may also provide incomplete
information. For example, data on inpatient medications will
be missing for both countries, as they are not mandatory for
reimbursement. We will then infer the prescribed anticoagulant
treatment during hospital stay from that prescribed just after
discharge using insurance claims data. Also, in Switzerland, we
will not be able to identify reasons for readmission or retransfer
to the same hospital within 18 days after discharge if the second
stay is grouped in the same Major Diagnostic Category as the
initial one. Indeed, according to the SwissDRG billing rules,
such a readmission or retransfer is merged with the initial
admission, leading to a single stay and discharge record.
Furthermore, Swiss hospital discharge data are limited to acute
care hospitals and do not cover hospital-at-home facilities, and
rehabilitation or psychiatric hospitals. Thromboembolic and
hemorrhagic adverse events occurring in these settings will thus
be missed except severe ones that would necessitate transfer to
acute care facilities.
Fourth, in both countries, neither hospital discharge data nor
insurance claims data contain individual information on causes
of death—which could be related to thromboembolic and
hemorrhagic adverse events—or on significant factors that
should be accounted for in GPSI case-mix adjustment. These
factors include, for example, genetic factors, demographic
characteristics (eg, ethnicity), clinical factors (eg, vital signs,
results from clinical examinations or laboratory tests),
health-related behaviors (eg, excessive alcohol consumption,
diet, and physical activity), health literacy, and patient
preferences or cultural beliefs [36].
Fifth, hospital discharge data may have potential limitations
regarding coding accuracy. In particular, the quality of
diagnostic and procedure coding may be affected by the quality
of patient record documentation, coders’ background, training,
and experience (eg, clinicians vs professional coders), coding
quality controls, and unintentional and intentional coding errors
(ie, “gaming” or “upcoding” to increase reimbursement)
[36,37,82,83]. Similarly, coding rules and classifications, coders’
characteristics, DRG classification systems, and coding quality
assurance policies (eg, coding quality controls, incentives for
coding, and penalties for inappropriate coding) may vary
significantly among health systems [21]. For example, Swiss
and French health systems differ on coding rules for the
“principal diagnosis” (ie, “condition responsible for resource
use” vs “reason for admission”) [84], mean numbers of
secondary diagnoses coded [21], medical coding classifications
for diagnoses (International Classification of Diseases, 10th
Revision [ICD-10], German Modification vs ICD-10 France)
and procedures (Swiss operation classification [CHOP] vs
French shared classification of medical procedures [CCAM]),
DRG classification systems (SwissDRG vs French Groupes
Homogènes de Malades), and coders’ profiles (professional
coders vs mixed profiles, including professional coders and
physicians). Limitations in coding quality may introduce
systematic bias in GPSI estimates and in comparisons among
hospitals, health territories, or countries, which cannot be
accounted for by risk adjustment [21,36,37,84,85]. Criterion
validity assessment will thus be essential to select valid GPSIs.
Moreover, regarding the possible influence of coding practice
to increase reimbursement, serious controls and financial
penalties are in place in Switzerland to limit this issue. Similarly,
serious controls are carried out in France, both at the hospital
and at the Technical Agency for Information on Hospital Care
(Agence Technique de l’Information sur l’Hospitalisation)
levels.
Sixth, we have decided to compare the quality of anticoagulant
prescription and surveillance across hospitals without adjusting
GQIs for differences in case mix. However, process indicators
may require case-mix adjustment when inpatients eligible to
receive the related process are not perfectly specified [51] or
when the “opportunity for violation of the standards” varies by
case mix [37]. Indeed, guidelines related to preventive and
curative anticoagulation do not account for older inpatients’
heterogeneity regarding their functional, cognitive, or social
disability, health conditions, and complexity. We will thus verify
that these conditions have no impact on GQI variations across
hospitals and health territories.
Seventh, criterion validity assessment based on retrospective
review of medical records may be less methodologically robust
than assessing GPSIs based on prospectively collected data [86].
Indeed, many adverse events are not recognized during the
process of clinical care without dedicated assessment, and they
are thus incompletely captured in medical records [87-90].
However, major adverse events will probably be well reported
in medical records, as they will contribute to the use of
additional resources in the hospital, and need to be reported for
appropriate reimbursement. Moreover, Klopotowska et al
showed that “[adverse drug events] with evident causality and
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with clinically apparent and severe consequences,” such as
adverse drug events resulting in hemorrhage or raised
international normalized ratio, are well recognized and
documented by medical teams [89]. In addition, the
implementation of more valid, but more resource-intensive,
studies would require important financial support that will not
be easy to obtain, neither from research agencies nor from health
care services.
Eighth, prior validation studies have suggested that, despite
good predictive and construct validity, AHRQ PSIs demonstrate
moderate sensitivity and PPVs in detecting surgical adverse
events [22]. Indeed, PSI algorithms usually favor specificity
over sensitivity and PPV [91]. Consequently, unless AHRQ PSI
validity is improved, more robust adverse event detection
methods (eg, prospective monitoring or voluntary patient safety
event reporting) should be preferred for internal quality
improvement, performance assessment, public reporting, and,
above all, pay for performance [83,91-93]. However, recent
validation studies contradict these results, at least for PSI-12
and PSI-09 [33,83,91]. Indeed, Mull et al showed that the
sensitivity of a PSI-12 algorithm based on ICD, 9th Revision,
Clinical Modification (ICD-9-CM) diagnosis and procedure
codes was 65% (95% CI 63%-67%). He also suggested that
PSI-12 sensitivity could be improved by using ICD-10-CM
codes [91]. Similarly, Utter et al reported that the sensitivity of
a PSI-09 algorithm based on ICD-9-CM codes could reach 85%
(95% CI 67%-94%) [33]. Regarding PPVs, Winters et al found,
based on a literature review and meta-analysis, pooled PPVs of
63.5% (95% CI 44.3%-82.7%) for PSI-12 and 78.6% (95% CI
73.2%-84.1%) for PSI-09 [83]. In our study, the detection of
anticoagulant-related adverse events should also be improved
by using hospital discharge data linked to insurance claims data.
Indeed, by adapting PSI-12 and PSI-09 algorithms to linked
data, Mull et al were able to capture 72% (with PSI-12) and
77% (with PSI-09) additional events occurring up to 30 days
after discharge [22]. Finally, in Switzerland, this research project
will be integrated into a larger research program, which will
aim to develop measures of anticoagulant-related
thromboembolic and hemorrhagic adverse events based on
structured (ie, administrative and clinical data) and textual data.
These measures should, in the end, have better sensitivity and
specificity than AHRQ PSIs. The larger research program has
just been funded by the Swiss National Fund.
Conclusions and Perspectives
This innovative study, which is part of a larger research program
aiming to develop and validate GPSIs and GQIs in both hospital
and ambulatory care settings, will provide valid and reliable
outcome and process indicators to assess older inpatient safety
related to anticoagulants. It should also provide new information
on real-life prevention and treatment of thromboembolism,
direct oral anticoagulant prescription and monitoring, and
hemorrhagic adverse events related to direct oral anticoagulants
in older patients. It should additionally contribute to describing
older inpatients’ characteristics and health professionals’
practices in Swiss and French hospital and ambulatory care
settings, and help identify geographic and temporal variations
in older patient safety related to the health system. Moreover,
within the frameworks of the Swiss Health 2020 policy agenda
and the French National Health Strategy, the comparative
assessment of hospitals and health territories using validated
GPSIs and GQIs could help inform health policies, promote
transparency, and improve health care efficiency.
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